(Q86625695)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634683%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

title

Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634683%20AND%20SRC:MED&resulttype=core&format=json

chronic lymphocytic leukemia

29 February 2020

main subject

1 reference

V Goede

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634683%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

K Fischer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634683%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

A Engelke

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634683%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

R Schlag

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634683%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

S Lepretre

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634683%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

L F C Montero

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634683%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

M Montillo

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634683%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

C Fegan

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634683%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

E Asikanius

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634683%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

K Humphrey

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634683%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

G Fingerle-Rowson

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634683%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

M Hallek

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634683%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

language of work or name

1 reference

30 January 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634683%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634683%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634683%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634683%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

page(s)

1602-1604

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634683%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2015.14

29 February 2020

exact match

0 references

cites work

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

1 reference

12 December 2020

Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells

1 reference

12 December 2020

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

1 reference

12 December 2020

Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models.

1 reference

12 December 2020

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

12 December 2020

Validation of the Cumulative Illness Rating Scale in a geriatric residential population

1 reference

12 December 2020

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

1 reference

12 December 2020

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

1 reference

12 December 2020

Prediction of creatinine clearance from serum creatinine

1 reference

12 December 2020

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

1 reference

12 December 2020

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

1 reference

12 December 2020

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

1 reference

12 December 2020

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia

1 reference

12 December 2020

Identifiers

DOI

10.1038/LEU.2015.14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25634683%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

29 February 2020

0 references

1 reference